T. Rowe Price Associates
KPTI icon

T. Rowe Price Associates’s Karyopharm Therapeutics KPTI Stock Holding History

T. Rowe Price Associates’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61K Hold
10,886
– – ﹤0.01% 3056
2025
Q4 		$81K Hold
10,886
– – ﹤0.01% 2971
2025
Q3 		$72K Hold
10,886
– – ﹤0.01% 2974
2025
Q2 		$47K Buy
+10,886
New +$53.4K ﹤0.01% 3013
2025
Q1 		– Sell
-4,287
Closed -$44K – 3059
2024
Q4 		$44K Sell
4,287
-4,693
-52% -$56.7K ﹤0.01% 2956
2024
Q3 		$112K Buy
8,980
+2,507
+39% +$31.2K ﹤0.01% 2796
2024
Q2 		$84K Buy
6,473
+134
+2% +$2.22K ﹤0.01% 2779
2024
Q1 		$144K Buy
6,339
+531
+9% +$9.31K ﹤0.01% 2703
2023
Q4 		$76K Hold
5,808
– – ﹤0.01% 2754
2023
Q3 		$117K Buy
5,808
+1,267
+28% +$28.4K ﹤0.01% 2630
2023
Q2 		$122K Buy
4,541
+510
+13% +$22K ﹤0.01% 2657
2023
Q1 		$236K Buy
4,031
+167
+4% +$8.24K ﹤0.01% 2453
2022
Q4 		$197K Buy
3,864
+362
+10% +$25.1K ﹤0.01% 2536
2022
Q3 		$287K Buy
3,502
+991
+39% +$74K ﹤0.01% 2403
2022
Q2 		$170K Buy
2,511
+758
+43% +$69.5K ﹤0.01% 2638
2022
Q1 		$194K Buy
1,753
+392
+29% +$48.9K ﹤0.01% 2722
2021
Q4 		$131K Sell
1,361
-1,633
-55% -$163K ﹤0.01% 2831
2021
Q3 		$261K Sell
2,994
-23,613
-89% -$2.45M ﹤0.01% 2626
2021
Q2 		$4.12M Sell
26,607
-6,257
-19% -$908K ﹤0.01% 1543
2021
Q1 		$5.19M Sell
32,864
-64,263
-66% -$13.5M ﹤0.01% 1460
2020
Q4 		$22.6M Buy
97,127
+1,326
+1% +$307K ﹤0.01% 1200
2020
Q3 		$21M Sell
95,801
-34,971
-27% -$8.55M ﹤0.01% 1144
2020
Q2 		$37.2M Buy
130,772
+37,789
+41% +$11.2M ﹤0.01% 947
2020
Q1 		$26.8M Buy
92,983
+81,666
+722% +$22.5M ﹤0.01% 977
2019
Q4 		$3.25M Buy
+11,317
New +$2.46M ﹤0.01% 1482
2017
Q4 		– Sell
-926
Closed -$153K – 2590
2017
Q3 		$153K Hold
926
– – ﹤0.01% 2452
2017
Q2 		$126K Buy
926
+1
+0.1% +$148 ﹤0.01% 2457
2017
Q1 		$178K Hold
925
– – ﹤0.01% 2417
2016
Q4 		$130K Hold
925
– – ﹤0.01% 2443
2016
Q3 		$135K Hold
925
– – ﹤0.01% 2404
2016
Q2 		$93K Sell
925
-2
-0.2% -$260 ﹤0.01% 2434
2016
Q1 		$124K Hold
927
– – ﹤0.01% 2383
2015
Q4 		$184K Buy
+927
New +$201K ﹤0.01% 2319

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

T. Rowe Price Associates's KPTI Position: Q1 2026 in Review

T. Rowe Price Associates held its Karyopharm Therapeutics (KPTI) position steady in Q1 2026 at 10,886 shares worth $61K. The position accounts for ﹤0.01% of the portfolio, ranked #3056.

T. Rowe Price Associates first reported a position in KPTI in Q4 2015 and has held it in 33 quarters since. The position peaked at $37.2M in Q2 2020. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • T. Rowe Price Associates held 10,886 shares of Karyopharm Therapeutics worth $61K as of Q1 2026.
  • T. Rowe Price Associates left its Karyopharm Therapeutics share count unchanged in Q1 2026.
  • Karyopharm Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #3056 holding.
  • T. Rowe Price Associates first reported a position in Karyopharm Therapeutics in Q4 2015 and has held it in 33 quarters since.
  • T. Rowe Price Associates's Karyopharm Therapeutics position peaked at $37.2M in Q2 2020.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.